News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Chiron Corporation (CHIR) Revises Reconciliation Of Pro-Forma And GAAP Full-Year 2004 Earnings Guidance



10/19/2005 5:11:47 PM

Chiron Corporation (Nasdaq:CHIR) announced today revised reconciliation of pro-forma and GAAP full-year 2004 earnings guidance. Chiron's full-year 2004 pro-forma earnings per share guidance of $0.70 to $0.80 per share excludes amortization expense on acquired intangible assets related to the acquisitions of PathoGenesis, Chiron Behring, Pulmopharm and PowderJect, and purchased in-process research and development charge related to the acquisition of Sagres totaling approximately $0.38 per share as opposed to $0.35 as reported on October 5, 2004. As a result, Chiron revises full-year 2004 GAAP earnings to between $0.32 to $0.42 per share.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES